Although clinical trials like BeGIN (NCT03872427) have yet to yield significant breakthroughs, these mechanistic insights continue to guide therapeutic strategies targeting the NRF2 antioxidant network in cancer. The gene discussed is NFE2L2; the disease is cancer.